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ABSTRACT
As medical technology evolves, clinicians are increasingly choosing relatively painless non-invasive methods of patient 
diagnosis and treatment. There are two principles behind this: greater patient comfort and lower cost. Tears, hair, saliva, 
urine, and faeces can replace blood for diagnosis. The varied constituents in these biological materials can serve as biomark-
ers for the detection of both local and systemic diseases. In this paper, we review a range of diagnostic techniques — all 
using biological material obtained via non-invasive procedure — for detecting medical conditions in pregnant women.
PubMed, Medline, Embase, and the Cochrane Library were searched from January 1996 until December 2018. Forty seven 
studies were included: thirty-five original articles, nine reviews and three meta-analysis.
Analysis showed that saliva, hair, tears, and other biological material — obtained via non-invasive methods — may serve 
as clinically informative biomarkers. These biomarkers may be used for: toxicology, psychological studies, disease detec-
tion, biomonitoring, and drug abuse. The analysis of tears, hair, saliva, urine, and faeces is a safe, noninvasive and useful 
diagnostic tool within groups of pregnant women, but further investigation is necessary to fully realize the promise of 
these novel diagnostic tools.
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INTRODUCTION
As medical technology evolves, clinicians are increas-
ingly choosing relatively painless non-invasive methods of 
patient diagnosis and treatment. There are two principles 
behind this: greater patient comfort and lower cost.
A milestone was achieved recently in fetal medicine: 
the debut of non-invasive testing via cell-free fetal DNA 
(cffDNA). Although still considered to be a method for 
screening rather than diagnosis, in certain cases cffDNA 
tests may be a useful option, replacing invasive tech-
niques such as amniocentesis or chorionic villous sam-
pling (CVS).
Tears, hair, saliva, urine, and faeces can replace blood 
for diagnosis. The varied constituents in these biological 
materials can serve as biomarkers for the detection of both 
local and systemic diseases. In this paper, we review a range 
of diagnostic techniques — all using biological material ob-
tained via non-invasive procedure — for detecting medical 
conditions in pregnant women.
Urine
Urine is a readily extractable biological fluid. Urine 
testing is an increasingly common non-invasive means of 
obtaining clinical data [1]. Such tests have an established 
part in maternal-fetal medical practice e.g. for detecting and 
monitoring proteinuria.
Due to its particular physiological function, urine is of-
ten characterized by irregular variation between individual 
persons, or at successive stages for a single individual. Large 
variations reflect urinary sensitivity to both normal physi-
ological change as well as abnormal pathological change in 
vivo [1]. In the absence of homeostatic mechanisms — and 
unlike blood — urinary variation may indicate more change, 
especially in the early stages of disease.  Urine samples can be 
collected long-term and painlessly. Moreover, urine collec-
tion is safer and cheaper than blood collection. Membrane 
technology [a new technique that absorbs urine proteins 
found on PVDF (polyvinylidene fluoride membrane), which 
can then be dried and stored] and other modern techniques, 
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have made collecting and storing urine samples even easier. 
Biomarkers found in urine may indicate the following:
ZIKV infection
Saliva and urine have been recognized for their value in 
diagnosing viruses such as Zika [2], which has seen a violent 
outbreak on a global scale. Zika may present in a milder form 
— lasting approximately one week — with symptoms such 
as rash, fever, myalgia, arthralgia, conjunctivitis, headache, 
and malaise. However, vertical transmission of the Zika virus 
may present fetal growth restriction, placental insufficiency, 
microcephaly, CNS, or even fetal death [3]. A recent study 
described the lower efficiency of experimental transmission 
for Zika’s main assumed vector: Aedes Aegypti, together 
with signs of probable sexual transmission. This led to 
consideration of other possible sources for Zika. Bonaldo 
et al. tested 5 saliva and 9 urine samples of patients from Rio 
de Janeiro. The results showed infectious Zika virions in the 
saliva and urine of patients in the acute stage, which may 
be a key factor in the dissemination of the virus. Bringhal et 
al. also tested saliva and urine, finding that: 95% (52/55) of 
urine samples taken from patients within 5 days of symptom 
appearance tested positive by RT-PCR; merely 56% (31/55) 
of serum samples taken on the same day tested positive by 
RT-PCR; 82% (9/11) of urine samples taken > 5 days after 
symptoms began tested positive by RT-PCR; zero RT-PCR 
tests for serum samples were positive. Such findings indicate 
that urine may be the best type of sample to detect the acute 
stage of Zika. Considering the importance of other non-
vectorial transmission routes, the epidemiological relevance 
of this calls for additional study.
Podocytes: a potential new biomarker for 
preeclampsia
There is no straightforward, cheap, dependable, test to 
predict with high accuracy whether preeclampsia will occur 
during pregnancy. The priority is to identify biomarkers 
— which should be non-invasively obtained and easily 
determined — to improve the efficient detection of this 
condition.  
There is growing evidence that the urinary excretion of 
viable podocytes may be a useful indicator of preeclamp-
sia. Garovic et al. extracted podocyte cells from urine in 
preeclamptic women. The study demonstrated a significant 
relationship between podocyturia and proteinuria. Fur-
thermore, it was shown that the quantity of podocyte cells 
excreted in urine is a sensitive indicator of renal damage as 
well as protein excretion among patients with preeclampsia. 
Another discovery was that urinary podocyte cells were 
absent in healthy pregnant women, as well as those present-
ing hypertension but no other preeclamptic symptoms [4]. 
Aita et al. [5] noted a strong link between podocyte quantity 
lost in urine and blood pressure, although not in the case of 
proteinuria. In 2012, Zhao et al. noticed a reduced expression 
of podocyte-slit diaphragm proteins — including polarity 
proteins, podocin, and nephrin — in preeclampsia. Tracing 
the relationship between urine podocyte cells and preec-
lampsia may show great promise, nonetheless, additional 
research is required [6]. 
SLOS
Non-invasive urine collection can identify the rarest of 
genetic fetal diseases. For example, the steroid metabolome, 
once extracted from maternal urine, can be used to confirm 
a diagnosis of Smith-Lemli-Opitz Syndrome (SLOS) [7]. The 
optimum standard for prenatal diagnosis is an increased 
level of 7-dehydrocholesterol (7-DHC), tested via either 
gas chromatography or mass spectrometry, and measured 
from the amniotic fluid after 14 weeks or from chorionic 
villous samples (CVS) between 10 and 12 weeks. Both 
amniocentesis and CVS are invasive procedures and risk 
miscarriage [8]. Consequently, testing specific steroid 
compounds (dehydroestriol, 7-dehydropregnanetriol, 
8-dehydropregnanetriol) in the maternal urine has been 
suggested as a non-invasive method for diagnosing SLOS [9]. 
Guo et al. have described how particular concentrations 
of these steroid compounds present in urine, with each 
SLOS analyte expressed as a ratio of its natural counterpart, 
can indicate SLOS between 14 and 22 weeks. This has been 
confirmed by other research such as Jezela-Stanek et al. [10] 
who successfully diagnosed prenatal SLOS employing 
maternal urine steroid ratios.
Faeces
Inflammatory bowel disease (IBD) is very common among 
adults of reproductive age [11]. When active, the condition 
increases risks associated with pregnancy, including 
preterm birth (PTB) and intrauterine growth restriction [12]. 
Possessing a recognized clinical tool to monitor IBD 
during pregnancy is an important, albeit challenging, care 
factor. In patients who are not pregnant, endoscopy is the 
optimum technique for assessing IBD severity. According 
to international guidelines, when an endoscopy is required, 
a sigmoidoscopy is usually the preferred method, ideally 
in the second trimester [13]. Employing other methods 
could be preferential when an endoscopy is unnecessary. 
Sedatives and extended procedures could harm maternal 
circulation. Consequently, non-invasive methods are of 
great value to monitor IBD.
One such method employs faecal calprotectin (FC) [14]. 
This is an accurate biomarker for mucosal inflammation, which 
correlates with histological inflammation as well as endoscopic 
activity [15]. Julsugaard et al. studied 46 pregnant women 
and found that FC is not affected by physiological changes 
477
Aleksandra Zygula et al., Saliva, hair, tears, and other biological materials obtained non-invasively for diagnosis in pregnancy: a literature review
www. journals.viamedica.pl/ginekologia_polska
occurring during pregnancy. Furthermore, the combination 
of the physician’s global assessment (PGA) and FC may be 
the best alternative to endoscopy for measuring disease 
activity. PGA and FC are also superior to other biomarkers 
such as the plasma concentration of C-reactive protein (CRP). 
The study also described how — instead of colonoscopy 
— FC could be employed to differentiate non-specific IBDs 
and distinguish them from irritable bowel syndrome [16]. 
However, no similar study has been carried out during 
pregnancy and thus additional research is required.
Tears
Tears are a mixture of proteins, mucins, lipids, 
salts, and water. A recent proteomic study discovered 
1526 proteins in tears [17], meaning that this biological 
fluid is less complex than either serum or plasma. 
Because of variations in the lacrimal functional unit 
(LFU), studying the composition of tears has been 
suggested as an ideal method for identifying biomarkers 
linked to different systemic disease ingredients [18]. 
Recent efforts have sought to identify new tear biomarkers 
for ocular diseases — e.g. dry eye disease (DED) symptomatic 
of diabetes — as well as systemic disease. Kan’s study was 
intended to assess tear function in pregnant women with 
gestational diabetes mellitus (GDM) [19]. The result was 
surprising: GDM appears to have no negative affect on tear 
function testing. This could be because of the absence of 
long-term hyperglycaemia, the presence of which may 
have affected tear function in pregnant women. As a readily 
obtainable biological fluid, tears could be employed in future 
medical testing, although this requires additional study.
Hair
Different methods of hair analysis are used for: toxicol-
ogy, anthropological studies, disease detection, biomoni-
toring, and drug abuse. Human hair is often a useful source 
of tissue sample as it is readily obtainable as well as stable. 
Furthermore, sample storage and preparation is straightfor-
ward: no specialised preservation method is needed. Hair 
— depending on its length — may signify a time period of 
days, months, or even years. Hair analysis is also extensively 
used in pregnancy.
FASD
An example of this would be testing maternal hair for 
ethyl glucuronide. Hair ethyl glucuronide (hEtG) is a bio-
marker for prenatal alcohol exposure. Alcohol consump-
tion may cause fetal abnormalities such as Fetal Alcohol 
Spectrum Disorder (FASD) or Intrauterine Growth Restriction 
(IUGR) [20]. Reducing the number of children harmed by 
prenatal alcohol exposure (PAE) can be achieved by early, 
accurate diagnosis of prenatal alcohol consumption, to-
gether with targeted harm reduction strategies [21]. One 
associated challenge concerns the high level of mater-
nal underreporting because of the social stigma around 
drinking alcohol during pregnancy. Consequently, further 
screening of biochemical alcohol biomarkers is called for. 
Because of its high sensitivity and specificity as an indicator 
of heavy chronic alcohol consumption, hEtG is a promising 
biomarker. Notwithstanding that, direct ethanol metabolites 
such as ethyl glucuronide (EtG) serve a key role in confirming 
PAE, although their utility may be reduced by their shorter 
half-life in blood and urine. Maternal hair analysis permits 
retrospective PAE analysis for several months. Screening 
blood or urine for alcohol biomarkers during the first pre-
natal visit gives negative results in many pregnant women 
who cease alcohol consumption upon realizing they are 
pregnant. Furthermore, hair analysis can indicate dangerous 
alcohol consumption in the periconceptional period — the 
critical stage of organogenesis. A meta-analysis of chronic 
alcohol users by Boscolo-Berto et al. (2014) [22] described 
an overall sensitivity of 96% and specificity of 99% for hEtG. 
Furthermore, hEtG — as a direct ethanol metabolite — has 
a higher specificity than other alcohol biomarkers tested in 
urine or blood. Such biomarkers are known to be affected by 
various maternal conditions and pregnancy related physi-
ological changes, including liver conditions, hypertension, 
gestational age, and iron deficiency. In light of these ad-
vantages, hEtG would appear to be a reliable biomarker for 
prenatal alcohol consumption.
Postpartum depression
Estimates suggest that rates of postpartum depres-
sion (PPD) in women range from 10–15%. Studies have 
long established how PPD can negatively affect the ma-
ternal-infant bond, as well as exacerbate outcomes in the 
child’s development — both physically and psychologi-
cally [23]. To prevent PPD onset and its negative effects, 
the early detection of PPD associated factors is necessary. 
The psychological or behavioural predictors for PPD in-
clude: age < 25, low-earnings, a history of miscarriages or 
terminations, PMS, antenatal depression, and antenatal 
anxiety. Although the above predictors are well known, 
there is a scarcity of biological forecasters. One promising 
PPD biomarker is hair cortisol. Measuring the levels of this 
hormone can detect chronic stress occurring in the prior 
three months. Unlike more typical samples — e.g. blood 
— situational variables or circadian rhythms do not affect 
this value [24]. Caparros-Gonzalez et al. studied 44 pregnant 
women over three pregnancy trimesters and the postpartum 
period; they employed psychological questionnaires and 
tested for hair cortisol levels. The study found significant 
variations in the hair cortisol levels between the groups with 
and the groups without symptoms of PPD in the first and 
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third trimesters [25]. Hair cortisol levels predicted 21.7% of 
PPD symptom variation. The research provided evidence 
that antenatal stress, psychopathological symptoms, and 
hair cortisol levels at various stages of pregnancy can pre-
dict PPD. These results encourage further research aimed at 
improving maternal care in clinical settings. To summarize, 
effective prenatal stress screening is both possible and meas-
urable. Consequently, it could be employed on a wider scale 
to reduce the harm caused by postnatal depression [26]. 
IVF success rate
Massey et al. [27] have studied women undergoing 
IVF treatment, examining the relationship between hair 
cortisol, salivary cortisol, and pregnancy. Results indicated 
that there was a significant negative association between 
concentrations of hair cortisol and clinical pregnancy 
outcomes (p = 0.017). The study offered preliminary evidence 
that longer-term systemic cortisol could have an effect 
upon pregnancy outcomes. Consequently, psychological 
intervention to lower cortisol levels prior to IVF treatment, such 
as CBT or mindfulness, could improve patient outcomes.
Fetal defects
Hair sample analysis is more reliable than blood analysis 
when measuring the concentration and chronic exposure 
of different metals in individual pregnant women [28]. Hair 
samples are more stable and easier to collect than blood. 
Studies on the concentration of metal in hair samples have 
given valuable insight on the potential origins of congenital 
defects. For example, a higher titanium level in a woman’s hair 
during periconception was linked with a greater risk of neu-
ral tube defects (NTD) in children. This could be partially miti-
gated by the mother’s diet [29]. Furthermore, exposure by the 
mother to cadmium and arsenic could significantly increase 
the risk of congenital heart defects (CHDs) in children [30]. 
An increased aluminum concentration in maternal hair may 
significantly increase the likelihood of a child being born 
with a CHD. Such conditions include conotruncal heart 
defect, septal defect, and right-sided obstructive heart de-
fect [31]. Because of the wide dissemination of the above 
metals in our 21st century lives, and their potential risk to 
a developing fetus, women should be strongly encouraged 
to adjust their diets during periconception and pregnancy. 
Testing hair samples can indicate when dietary and lifestyle 
changes should be introduced by pregnant women; the 
implementation of such changes could lead to a fall in the 
number of fetal abnormalities. 
Predictors of viral suppression in women  
infected with HIV
It is recognized that sufficient antiretroviral drugs (ARV) 
can protect HIV infected pregnant women and decrease 
the risk of viral transmission to children. Unfortunately, 
drug compliance can be compromised by psychological 
changes occurring during pregnancy. This — combined with 
altered drug barriers — can affect ARV pharmacokinetics, 
potentially limiting drug exposure. There is therefore 
an urgent need for an objective means of measuring ARV 
compliance in pregnant women. The most commonly tested 
biological sample for repetitive drug use during pregnancy 
is maternal hair. Hair grows at a rate of 1 cm per month; it is 
thereby possible to assess the pattern of drug compliance 
over three trimesters [32].
PROMOTE was a Ugandan study on HIV-infected preg-
nant women at 12–28 weeks, who were randomly assigned 
either lopinavir or efavirenz-based antiretroviral therapy 
(ART) [33]. The study concluded that measuring ARV con-
centrations in subjects’ hair was a promising method for 
accurately predicting viral suppression among them. The 
technique could lower the risk of perinatal HIV transmission 
during the critical stages of delivery and breastfeeding.
Saliva
Clinicians first used saliva for medical diagnosis after 
WW2 [34]. Known as the “mirror of body health”, saliva indi-
cates both the local and general health of a patient. It is used 
to detect key biomarkers of both oral and systemic diseases, 
as well as indicating an individual’s exposure to varied sub-
stances. Recently, saliva testing has become a recommended 
means for detecting body fluid biomarkers, since it is cheap, 
non-invasive and painless [35]. Furthermore, saliva does not 
clot, is less prone to potential infection, and can be easily 
collected, carried, and kept. 
Preterm birth
One tenth of deliveries are preterm; this is the second 
main cause of neonatal morbidity and mortality. It has proved 
difficult to identify an optimum biomarker to accurately 
predict those women who will deliver preterm. Although 
various current biochemical and biophysical markers have 
been investigated, a reliably accurate biomarker has yet to 
be found [36]. Priya et al. [37] tested levels of progesterone 
in the saliva of asymptomatic high‐risk women to predict 
PTB, comparing this with transvaginal sonographic (TVS) 
cervix length. The study examined asymptomatic women 
(n = 90) with singleton pregnancies at 24–28 weeks. Subjects 
had a history of PTB, preterm pre-labour membrane rupture, 
or late spontaneous miscarriage (at 20–28 weeks). Results 
showed a positive linear correlation between TVS cervix 
length and progesterone levels in the saliva. This suggests 
that the change in TVS cervix length may be indicated by 
the concentration of progesterone in the saliva. The two 
tests were compared; salivary progesterone was found to be 
a better predictor of PTB than cervix length at < 34 weeks, 
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but not at < 37 weeks. This may suggest that the cervix 
becomes shorter followed by a decrease in progesterone. It 
is desirable to isolate the subset of women who could gain 
maximum benefit from progesterone supplements from 
a larger set of high‐risk asymptomatic women; this can be 
achieved by measuring progesterone levels in the saliva. 
The study underlined that a low level of progesterone in the 
saliva (< 2575 pg/mL) at 24–32 weeks can identify women 
at risk of PTB.
Monitoring of prenatal smokers
Smoking is the No.1 cause of avoidable mortality in 
women and a main preventable cause of negative pregnancy 
outcomes in high-income economies. The most serious 
health conditions linked to maternal smoking include: 
preeclampsia [38], placental abruption, uteroplacental 
insufficiency, premature membrane rupture, decreased 
blood flow to the fetus, as well as intrauterine growth 
retardation [39]. Due to the quantity of severe health 
conditions linked to smoking, it is essential to both 
monitor exposure and encourage quitting. Initial smoking 
assessment in pregnant women is often based on self-
reporting via a questionnaire. However, with the increase in 
stigma around smoking during pregnancy, there is a higher 
probability that women will not self-report their smoking. 
Biochemical verification — by means of non-invasive 
techniques such as saliva or urine tests — can assess smok-
ing prevalence with greater reliability. Being a matrix, sa-
liva can be destroyed easier than urine; it is therefore used 
for fast screening of smoking status. Studies performed in 
high-income economies have shown that pregnant wom-
en’s self-reporting of smoking can underestimate prevalence 
by 24–28% [40, 41]. The difference may be explained by the 
raised awareness of the risks of smoking while pregnant, 
combined with increased stigma towards pregnant smokers.
To conclude, self-reporting is an unreliable measure of 
smoking in pregnancy. Since it underestimates the number 
of smokers, additional screening for biomarkers of nicotine 
intake is required. The concentration of salivary cotinine 
appears to be an accurate biomarker, which permits active 
smokers to be separated from passive [42]. An important 
benefit of cotinine over nicotine as a biomarker for smok-
ing is that approximately 72% of nicotine is converted into 
cotinine. The half-life of cotinine averages around 17 h com-
pared to 2–3 h for nicotine. The saliva cotinine cut-off level 
for active smokers was 10 ng/mL (sensitivity 96%, specificity 
95%) while for passive smokers it was 1.5 ng/mL (sensitivity 
63%, specificity 71%) [43].
GDM and oxidative stress
Oxidative stress (OS) is thought to be the key factor 
in the development and progress of gestational diabetes 
mellitus (GDM). It also plays a role in complications related 
to GDM, including pregnancy-induced hypertension and 
intrauterine growth retardation [44]. A useful biomarker 
for testing oxidative stress levels in GDM populations 
is saliva [45]. Zygula et al. studied 89 pregnant women 
(n = 89; GDM = 59; control = 30). The saliva of each 
subject was analyzed for malondialdehyde (MDA), total 
antioxidant capacity (ORAC), and inactivation of aldehyde 
dehydrogenase (IALDH). Oxidative stress was not found 
in GDMG1 but was found to be moderate in GDMG2. In 
GDMG2, higher concentrations of salivary MDA and IALDH 
were found. Salivary OS was correlated with — and found 
to be most significant for — ORAC. Salivary ORAC could be 
a systemic biomarker for oxidative stress [45]. Salivary MDA 
and the inactivation of ALDH could be biomarkers for OS 
in the oral cavity. Screening the saliva of pregnant women 
for OS biomarkers could prove beneficial for oral health 
problems, gestational diabetes, or even premature delivery 
[46]. One study found that MT2A present in saliva could be 
a potential biomarker for the risk of premature delivery. 
Notwithstanding this, additional research is necessary to 
confirm these results [46].
Glucose nano-biosensor
The finger-prick test is part of standard diabetes 
management, which is painful and inconvenient for self-
monitoring patients. Non-invasive glucose testing could 
improve compliance and glucose control, as well as decreasing 
both the complexity and costs of disease management. 
A new disposable on-chip salivary nano-biosensor has been 
suggested as a non-invasive technique. The working electrode 
is functionalized with single-walled carbon nanotubes, 
chitosan multilayers, gold nanoparticles, and glucose oxidase, 
with layer-by-layer assembly. The biosensor can detect glucose 
to 0.1 mg/dL and gives results in 30 seconds. Studies have 
shown that these salivary biosensors are a reliable, reproducible 
and efficient technology, which enables continuous salivary 
glucose monitoring [47].
SUMMARY
Saliva, hair, tears, and other biological material — ob-
tained via non-invasive methods — can serve as clinically 
informative biomarkers. Multiple studies have described 
how these biomarkers can be used in new techniques for 
prognosis, laboratory or clinical diagnosis, observation, 
and management of patients with varied medical condi-
tions. Biological samples — which contain soluble biological 
markers — have the advantage of being easily collected and 
stored. These biomarkers can also be used within groups 
of pregnant women to detect various diseases or medical 
conditions. However, further research is necessary to fully 
realise the benefits of these novel approach to diagnostic.
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